Male Sprague‑Dawley rats (n = 4 per group) received Mukd‑546 either intravenously (2 mg·kg⁻¹) or orally (10 mg·kg⁻¹). Plasma samples collected up to 24 h, quantified by LC‑MS/MS (LLOQ = 1 ng·mL⁻¹). PK parameters (C_max, AUC₀‑∞, t₁/₂, bioavailability) calculated using Phoenix WinNonlin.
This study presents a comprehensive pre‑clinical assessment of Mukd‑546, spanning computational modeling, biochemical selectivity profiling, cellular pharmacodynamics, pharmacokinetics, and efficacy in mouse xenograft models. mukd-546
Mice were randomized (Day 7, when tumors reached ~100 mm³) to receive either vehicle (0.5 % methylcellulose) or Mukd‑546 (30 mg·kg⁻¹, oral gavage, QD) for 21 days. Tumor volumes measured twice weekly (V = ½ × length × width²). Body weight and clinical signs monitored. At endpoint, tumors were harvested for immunohistochemistry (IHC) of p‑ERK and Ki‑67. Male Sprague‑Dawley rats (n = 4 per group)
A. Patel (email: a.patel@cam.ac.uk)